CompanyDYNNasdaqWaltham, MA

Dyne Therapeutics

Dyne Therapeutics develops therapies targeting muscle and the central nervous system for genetically driven neuromuscular diseases.

SEC EDGAR ClinicalTrials.gov dyne-tx.com

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

Dyne reports new one-year data from ACHIEVE trial of z-basivarsen in DM1

Sep 29Clinical readoutDyne Therapeutics

July 2026

Dyne reports Q2 2026 results as FDA accepts BLA for z-rostudirsen

Jul 29Quarterly updateDyne Therapeutics

Dyne Therapeutics prices upsized $375 million stock offering at $20.50 a share

Jul 22FinancingDyne Therapeutics

VCU registers END-EXT natural history study for myotonic dystrophy type 1; Dyne, Vertex collaborate

Jul 13Trial updateDyne Therapeutics Vertex Pharmaceuticals Inc / Ma